NASDAQ : BGLC
BioNexus Gene Lab Corp. — Key statistics
Materials · Specialty Chemicals · Malaysia
Last price 0.98 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 2.87M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 2.69M |
| Enterprise Value | -506,902 |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 2.93M |
| Shares Outstanding | 2.93M |
| Shares Change (YoY) | +20.61% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 29.66% |
| Owned by Institutions (%) | 6.46% |
| Float | 1.67M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.86 |
| Forward PS | n/a |
| PB Ratio | 0.29 |
| P/TBV Ratio | 0.35 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 6.08 |
| Quick Ratio | 4.56 |
| Debt / Equity | 0.04 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -163.17 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -33.66% |
| Return on Assets (ROA) | -18.99% |
| Return on Invested Capital (ROIC) | -60.88% |
| Return on Capital Employed (ROCE) | -34.83% |
| Weighted Average Cost of Capital (WACC) | 15.03% |
| Revenue Per Employee | $164,557 |
| Profits Per Employee | -$135,533 |
| Employee Count | 19 |
| Asset Turnover | 0.34 |
| Inventory Turnover | 2.93 |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 2.20 |
| 52-Week Price Change | -82.08% |
| 50-Day Moving Average | 1.35 |
| 200-Day Moving Average | 1.99 |
| Relative Strength Index (RSI) | 24.46 |
| Average Volume (20 Days) | 5,992 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 9,051 |
| Short Previous Month | 10,111 |
| Short % of Shares Out | 0.31% |
| Short % of Float | 0.54% |
| Short Ratio (days to cover) | 0.92 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 3.13M |
| Gross Profit | 385,894 |
| Operating Income | -2.76M |
| Pretax Income | -2.58M |
| Net Income | -2.58M |
| EBITDA | -2.64M |
| EBIT | -2.76M |
| Loss Per Share | -$1.19 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 3.52M |
| Total Debt | 323,197 |
| Net Cash | 3.20M |
| Net Cash Per Share | $1.09 |
| Equity (Book Value) | 7.78M |
| Book Value Per Share | 3.22 |
| Working Capital | 4.13M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -846,565 |
| Capital Expenditures | -7,035 |
| Depreciation & Amortization | 116,512 |
| Net Borrowing | 107,006 |
| Free Cash Flow | -853,600 |
| FCF Per Share | -$0.29 |
Margins
| Measure | Value |
|---|
| Gross Margin | 12.34% |
| Operating Margin | -88.16% |
| Pretax Margin | -82.36% |
| Profit Margin | -82.36% |
| EBITDA Margin | -84.44% |
| EBIT Margin | -88.16% |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -20.61% |
| Shareholder Yield | -20.61% |
| Earnings Yield | -129.52% |
| FCF Yield | -31.72% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Apr 7, 2025 |
| Split Type | Reverse |
| Split Ratio | 1:10 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 3.65 |
| Piotroski F-Score | 2 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |